Commonwealth Equity Services LLC Grows Stock Position in United Therapeutics Corporation $UTHR

Commonwealth Equity Services LLC grew its position in United Therapeutics Corporation (NASDAQ:UTHR) by 19.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,293 shares of the biotechnology company’s stock after acquiring an additional 1,196 shares during the quarter. Commonwealth Equity Services LLC’s holdings in United Therapeutics were worth $3,554,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in UTHR. Geneos Wealth Management Inc. lifted its position in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 70 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $277,000. Cerity Partners LLC increased its holdings in shares of United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia increased its holdings in shares of United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $547.07, for a total value of $4,540,681.00. Following the sale, the executive vice president owned 45,172 shares in the company, valued at $24,712,246.04. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Friday, June 5th. The shares were sold at an average price of $547.62, for a total value of $5,202,390.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,185,729.06. The trade was a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 624,043 shares of company stock worth $351,930,785 over the last quarter. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Stock Down 0.9%

NASDAQ:UTHR opened at $544.69 on Tuesday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The company has a market capitalization of $23.12 billion, a P/E ratio of 20.11, a P/E/G ratio of 1.79 and a beta of 0.57. The stock’s fifty day moving average is $568.47 and its two-hundred day moving average is $519.64.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the prior year, the firm earned $6.63 EPS. United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. Sell-side analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of several recent research reports. Cantor Fitzgerald increased their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Bank of America increased their price target on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. UBS Group increased their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Finally, TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.